2014

ADVANCE-ON Collaborative Group. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. September 2014. DOI:10.1056/NEJMoa1407963.
Full article

2013

Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial. Hypertension. 2013;63:259-264.
Abstract

Batty GD, Li Q, Huxley R, et al. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Eur Psychiatry. 2013;28:49-52.
Abstract

Hata J, Arima H, Zoungas S, et al. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One. 2013;8:e55807.
Abstract

Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013 Mar;83:517-523.
Abstract

Wong MG, Perkovic V, Woodward M, et al. Circulating bone morphogenetic protein-7 and transforming growth factor-ß1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int. 2013;83:278-284.
Abstract

Zaman MJ, Patel A, Chalmers J, et al. The effects of patient characteristics and geographical region on hospitalization in patients with Type 2 diabetes. Diabet Med. 2013 Mar 27. [Epub ahead of print].
Abstract

2012

Hillis GS, Hata J, Woodward M, et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2012;1:e002832.
Abstract

Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:1283-1290.
Abstract

Jardine MJ, Hata J, Woodward M, et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis. 2012;60:770-778.
Abstract

Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001293.
Abstract

Morton J, Zoungas S, Li Q, et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care. 2012;35:2201-2206.
Abstract

van Dieren S, Czernichow S, Chalmers J, et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab. 2012;14:464-469.
Abstract

van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83-90.
Abstract

Wong G, Zoungas S, Lo S, et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrol Dial Transplant. 2012;27:3337-3344.
Abstract

Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636-643.
Abstract

Zoungas S, Chalmers J. Diabetes: glycemic control and outcomes in people with diabetes and CKD. Nat Rev Nephrol. 2012;8:133-134.
Abstract

Zoungas S, Chalmers J, Li Q, Woodward M. ADVANCE and glycaemia thresholds: a need to clarify the statistical approach. Reply to Currie CJ [letter]. Diabetologia. 2012;55:2300.
Abstract

2011

Brugts JJ, Isaacs A, de Maat MP, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011;29:509-519.
Abstract

Czernichow S, Kengne AP, Huxley RR, et al. Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. Eur J Cardiovasc Prev Rehabil. 2011;18:312-319.
Abstract

Doughty RN, Whalley GA, Gamble GD, et al. Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. J Hypertens. 2011;29:1439-1447.
Abstract

Kengne AP, Patel A, Marre M, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18:393-398.
Abstract

Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK. Metabolic sequelae of ß-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond). 2011;35:1395-1403.
Abstract

Salomon JA, Patel A, Neal B, et al. Comparability of patient-reported health status: multicountry analysis of EQ-5D responses in patients with type 2 diabetes. Med Care. 2011;49:962-970.
Abstract

Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011;54:1608-1614.
Abstract

Woodward M, Patel A, Zoungas S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care. 2011;34:2491-2495.
Abstract

Zoungas S, Woodward M. Insights from the extended follow-up of the ACCORD trial. Nat Rev Cardiol. 2011;8:308-310.
Abstract

2010

Batty GD, Li Q, Czernichow S, et al. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol. 2010;56:1908-1913.
Abstract

Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol. 2010;55:340-347.
Abstract

Glasziou PP, Clarke P, Alexander J, et al. Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. Med J Aust. 2010;193:320-324.
Abstract

Heerspink HJ, Ninomiya T, Perkovic V, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31:2888-2896.
Abstract

Lee CC, Stolk RP, Adler AI, et al. Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem Study. Diabet Med. 2010;27:1130-1137.
Abstract

Li Q, Chalmers J, Czernichow S, et al. Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2010;53:2320-2327.
Abstract

Ninomiya T, Zoungas S, Neal B, et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens. 2010;28:1141-1149.
Abstract

Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89:126-133.
Abstract

Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418.
Abstract

Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, Salomon JA on behalf of the ADVANCE Collaborative Group. Event rates, hospital utilization, and costs associated with major complications of diabetes: A multicountry comparative analysis. PLOS Medicine 2010;7(2)e1000236.

Kengne A P, Patel A, Colagiuri S, Heller S, Hamet P, Marre M, Pan CY, Zoungas S, Grobbee D, Neal B, Chalmers J, Woodward M. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetelogia 2010;53(5):821-31.

2009

B C, Ninomiya T, Patel A A, Paul S K, Travert F, Woodward M for the Collaborators on Trial of Lowering Glucose (CONTROL) writing group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetelogia 2009. 52:2288-2298.Zoungas S, Chalmers J, Patel A.

Cardiovascular risk in Type 2 diabetes – reflecting on the ADVANCE Study. European Endocrinology 2009;5(1):42-46. [IF: NA] Also published in: US Endocrinology 2009;5(1):95-99.de Galan BE, Zoungas S, Chalmers J, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52:2328-2336.
Abstract

Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32:2068-2074.
Abstract

Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52:2027-2036.
Abstract

Brugts JJ, Ninomiya T, Boersma E, and al. The consistency of the treatment effect of an ACE-inhibitor-based treatment regimen in patients with vascular disease or high-risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS-trials comparing perindopril-indapamide versus placebo. Eur. Heart J. 2009;30: 1385-394.
Abstract

Du X, Ninomiya T, de Galan B, and al., on behalf of the ADVANCE Collaborative Group. Risk of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and artrial fibrillation – results of the ADVANCE study. Eur. Heart J. 2009;30:1128-1135.
Abstract

Joshi R, Galan B, Chalmers J, Perkovic V, Patel A. Routine blood pressure lowering and intensive glucose control in patients with type 2 diabetes: Results from the ADVANCE trial. Exp. Rev. Endocrinol Metab. 2009 4(2), 111-118.

Kengne A-P, Czernichow S, Huxley Rm Grobbee D, and al. Blood pressure variables and cardiovascular risk: New findings from ADVANCE. Hypertension 2009 54:399-404.
Abstract

Ninomiya T, Perkovic V, de Galan BE, and al., on behalf of the ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. NephroL. 2009 20:1813-1821.
Abstract

2008 

Patel A, Chalmers J, MacMahon S, Neal B. ADVANCE Blood pressure lowering in diabetes. J. Clin. Hypert. 2008;11:108. (Letter).
Abstract

de Galan B, Perkovic V, Ninomiya T, and al., on behalf of the ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 2009;20:883-892.
Abstract

Patel A, MacMahon S, Chalmers J, on behalf of the ADVANCE Collaborative Group. Intensive Glucose Control in Type 2 Diabetes – the author’s reply. N. Engl. J. Med. 2008;359:1519-1521. (Letter)Chalmers J, Cooper M. UKPDS and the legacy effects. N. Engl. J. Med. 2008;359:1618-1620. (Editorial)
Abstract

Chalmers J and Zanchetti A. Advances in the prevention of cardiovascular diseases in patients with diabetes. J. Hypertens. 2008;26(Suppl 3) S1-S2.Chalmers J, Joshi R, Kengne A-P, and al., on behalf of the ADVANCE Collaborative Group. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of evidence available in 2007. J. Hypertens. 2008;26(Suppl 3) S21-S28.
Abstract

Chalmers J, Joshi R, Kengne A-P, MacMahon S. Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. J.Hypertens. Suppl. 2008; 26(Suppl2);S11-S15.
Abstract

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
Abstract

Chalmers J, Joshi R, Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 2008;35:434-437.
Abstract

Patel A, MacMahon S, Neal B, Billot L, Chalmers J, on behalf of the ADVANCE Collaborative Group. The ADVANCE Trial – the author’s reply. Lancet 2008;371:25-26.

2007 

Chalmers J and Zanchetti A. Introduction : Hypertension in patients with diabetes: Can the treatment of macro and microvascular events be improved? Rationale of the ADVANCE Study. Editorial for the 5th Franco-Italian Meeting on Hypertension, Rome 2006. J. Hypertens. 2007;25(Suppl1):S1-S2.Glasziou P, Alexander J, Beller E, Clarke P and the ADVANCE Collaborative Group (Chalmers J, Chairman). Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual. Life Outcomes, 2007;5:21 doi 10.1186/1477-7525-5-21 [Epub ahead of print].
Abstract

Chalmers J, Kengne A-P, Joshi R, Perkovic V and Patel A. New insights from ADVANCE. J. Hypertens.2007;25 (Suppl 1):S23-S30.
Abstract

Patel A, MacMahon S, Chalmers J, and al., on behalf of the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.
Abstract

Monaghan H., Richens A., Colman S., and al. A randomised trial of the effects of an additional communication strategy on recruitment into a large-scale, multi-centre trial. Contemp. Clin. Trials 2007;28:1-5.
Abstract

Stolk R.P., Vingerling J.R., Cruickshank J.K., and al, on behalf of the AdRem project team and ADVANCE Management Committee. Rationale and design of the AdRem study : Evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemporary Clinical Trials 2007 28:1:6-17.
Abstract

2006

Perkovic V, Joshi R, Patel A, Bompoint S, Chalmers J on behalf of the ADVANCE Collaborative Group. ADVANCE: Lessons from the run-in phase of a large study in type 2 diabetes. Blood Press. 2006;15:340-346.
Abstract

Chalmers J, Perkovic V, Joshi R, Patel A. ADVANCE: Breaking new ground in type 2 diabetes. J. Hypertens. 2006; 24 suppl 5): S22-S28.
Abstract

2005

Patel A., Chalmers J. and Poulter N. ADVANCE: action in diabetes and vascular disease. J. Hum. Hypertens. 2005;19:S27-S32.
Abstract

ADVANCE Collaborative Group. ADVANCE – Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study at baseline. Diabet. Med. 2005:22:882-888.
Abstract

2004

Chalmers J. Nouvelles stratégies pour le contrôle de l’hypertension: preuves supplémentaries en faveur des associations faiblement dosées. (New Strategies for hypertension control : more evidence for low-dose combination therapy). A. J. Cardiovas. Drugs 2004; 4:1 :37-42.

2003

Grobbee DE. How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. Metabolism. 2003;52(8 Suppl 1):24-28.
Abstract

Patel A., Chalmers J., Chaturvedi V. and al. Diabetes and Vascular disease – a New International Trial. Asian.Cardiovas. 2003;11:180-184.
Abstract

Chalmers J. ADVANCE study: objectives, design and current status. [Article in French] Drugs. 2003;63 Spec No 1:39-44.
Abstract

2001

Patel A, Chalmers J, Neal B, Chapman N, Girgis S, MacMahon S. Blood Pressure Lowering in Diabetes: a brief review of the current evidence and description of a new trial. Clini. Exp. Pharmacol. Physiol. 2001;28;1108-1111.
Abstract

ADVANCE Collaborative Group. Rationale and Design of the ADVANCE Study: A randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes. J. Hypertens. 2001;19 (Suppl 4):S21-S28.
Abstract

ADVANCE Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44:1118-1120.
Abstract